Sign in →

Test Code GALU Galactose, Quantitative, Random, Urine

Additional Codes

Torrance Memorial Laboratories Test Code:  448886646
 

Reporting Name

Galactose, QN, U

Useful For

Screening test for galactosemia using urine specimens

Testing Algorithm

For information, see Galactosemia Testing Algorithm.

Method Name

Spectrophotometric/Kinetic

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Specimen Type

Urine


Ordering Guidance


This test is not recommended for follow-up of positive newborn screening results or for diagnosis of galactosemia. The preferred test to evaluate for possible diagnosis of galactosemia, routine carrier screening, and follow-up of abnormal newborn screening results is GCT / Galactosemia Reflex, Blood along with GAL1P / Galactose-1-Phosphate, Erythrocytes.

 

This test is not appropriate for monitoring of galactosemia. For monitoring, order GAL1P / Galactose-1-Phosphate, Erythrocytes.



Necessary Information


Biochemical Genetics Patient Information (T602) is recommended, but not required, to be filled out and sent with the specimen to aid in the interpretation of test results.



Specimen Required


Supplies: Sarstedt Aliquot Tube, 5 mL (T914)

Collection Container/Tube: Clean, plastic urine collection container

Submission Container/Tube: Plastic, 5-mL tube

Specimen Volume: 1 mL

Collection Instructions: Collect a random urine specimen.


Specimen Stability Information

Specimen Type Temperature Time Special Container
Urine Frozen (preferred) 365 days
  Ambient  20 days
  Refrigerated  20 days

Reject Due To

  All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.

Reference Values

<30 mg/dL

Day(s) Performed

Tuesday

Report Available

4 to 10 days

CPT Code Information

82760

LOINC Code Information

Test ID Test Order Name Order LOINC Value
GALU Galactose, QN, U 2310-1

 

Result ID Test Result Name Result LOINC Value
8765 Galactose, QN, U 2310-1

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

Forms

Biochemical Genetics Patient Information (T602) is recommended.